Non-active stimulation

DEVICE2 trials

Sponsors

SetPoint Medical Corporation

Conditions

Relapsing Remitting Multiple SclerosisRheumatoid Arthritis

Phase 3

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruitingNCT04539964

SetPoint Medical CorporationRheumatoid Arthritis

Start: 2021-01-11End: 2027-10-01Updated: 2026-04-14

Unknown Phase

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

RecruitingNCT06796504

SetPoint Medical CorporationRelapsing Remitting Multiple Sclerosis

Start: 2026-04-17End: 2030-09-30Target: 60Updated: 2026-09-02

Related Papers

Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial.

2025-12-22

Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study.

2024-03-1313 citations

GLIOMA-05 A NOVEL CONCEPT FOR TREATMENT OF GLIOBLASTOMA: VAGUS NERVE ELECTRICAL STIMULATION FOR SUPPRESSION OF CYTOKINE (IL-6) SIGNALING

Neuro-Oncology Advances2023-10-311 citations